Carnitine Supplementation and Skeletal Muscle Function

Gdansk University of Physical Education and Sport

Status and phase: Completed; Phase 3

Conditions: Sarcopenia

Treatments: Dietary Supplement: carnitine; Dietary Supplement: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02692235

2014/15/B/NZ7/00893

Details and patient eligibility

About

Research project objectives The primary aim of the current research project is to use carnitine supplementation as the anti-inflammatory intervention for exploring the relationship between inflammation and associated with aging reduction of skeletal muscle mass.

Hypothesis The carnitine supplementation modulates the blood cytokines concentration. Anti-inflammatory intervention delay the reduction of skeletal muscle mass associated with aging

Full description

Volunteers over 65 years old (n=40) are supplemented either with carnitine or placebo for 24 weeks. Before the start, in the mid-point, and after finishing the supplementation the following primary outputs variables are performed: body composition analysis (InBody720), maximal isokinetic knee extensor peak torque (Biodex System 4 Pro), blood cytokines and carnitine concentration, blood lipid profile.

Enrollment: 28 patients

Sex: All

Ages: 65 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects with no history of gastrointestinal disorders, cardiovascular disease or hypertension.

Exclusion criteria

• Subjects having any illnesses and a history of gastrointestinal disorder, cardiovascular disease, hypertension, liver and renal disease, diabetes, cancer, alcoholism or other metabolic diseases.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

28 participants in 2 patient groups, including a placebo group

carnitine

Experimental group

Description:

24 weeks l-carnitine-l-tartrate supplementation

Treatment:

Dietary Supplement: carnitine

placebo

Placebo Comparator group

Description:

24 weeks isonitrogenous supplementation

Treatment:

Dietary Supplement: placebo